Bristol Myers Squibb Expands Portfolio with RayzeBio Acquisition, Gaining Ground in Radiopharmaceutical Therapeutics
In a recent announcement, Bristol Myers Squibb (BMS) proudly declared the successful finalization of its acquisition of RayzeBio, Inc., a prominent player in the field of radiopharmaceutical therapeutics (RPTs). With th...
Feb 26, 2024
• Major Pharmaceutical Preparations Industry
Business Update
NASDAQ
